Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLYC NASDAQ:NMTR NASDAQ:THTX NASDAQ:TLC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLYCGlycoMimetics$0.16-6.6%$14.00$14.06▼$63.00$10.00M1.6265,430 shs1.05 million shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shs1,648 shsTHTXTheratechnologies$3.15+0.3%$2.63$1.12▼$3.20$144.84M0.55890,821 shs409,125 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLYCGlycoMimetics0.00%0.00%-99.12%-99.20%-99.43%NMTR9 Meters Biopharma0.00%0.00%0.00%0.00%+6,463.64%THTXTheratechnologies0.00%+33.05%+20.77%+136.09%+105.23%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGLYCGlycoMimetics1.1836 of 5 stars0.03.00.04.61.11.70.0NMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLYCGlycoMimetics 2.50Moderate BuyN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/ATHTXTheratechnologies 3.00BuyN/AN/ATLCTaiwan Liposome 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest THTX, GLYC, TLC, and NMTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/11/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLYCGlycoMimetics$10K1,000.25N/AN/A$0.08 per share1.94NMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/ATHTXTheratechnologies$88.67M1.63N/AN/A($0.55) per share-5.73TLCTaiwan Liposome$3.63M81.14N/AN/A$0.83 per share8.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%8/6/2025 (Estimated)NMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/ATHTXTheratechnologies-$8.31M-$0.08N/A45.00N/A-4.18%N/A-0.37%N/ATLCTaiwan Liposome-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/ALatest THTX, GLYC, TLC, and NMTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/9/2025Q2 2025THTXTheratechnologies-$0.01-$0.09-$0.08-$0.09$24.30 million$17,729.00 billion5/14/2025Q1 2025GLYCGlycoMimetics-$5.00-$4.00+$1.00-$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLYCGlycoMimeticsN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLYCGlycoMimeticsN/A1.921.92NMTR9 Meters BiopharmaN/A0.590.59THTXTheratechnologiesN/A1.080.88TLCTaiwan Liposome0.673.013.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLYCGlycoMimetics75.19%NMTR9 Meters Biopharma22.34%THTXTheratechnologiesN/ATLCTaiwan Liposome0.22%Insider OwnershipCompanyInsider OwnershipGLYCGlycoMimetics8.70%NMTR9 Meters Biopharma2.40%THTXTheratechnologiesN/ATLCTaiwan LiposomeN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLYCGlycoMimetics5064.53 million58.90 millionOptionableNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataTHTXTheratechnologies14045.98 millionN/AOptionableTLCTaiwan Liposome2,02042.08 millionN/ANot OptionableTHTX, GLYC, TLC, and NMTR HeadlinesRecent News About These CompaniesTLC’s ‘My Big Fat Fabulous Life’: Whitney undergoes womb cleansing ceremonyJuly 9 at 7:53 PM | msn.comTLC Reality Star, 27, Accused of Verbal Abuse in Shocking Audio Shared by ExJuly 9 at 7:53 PM | au.lifestyle.yahoo.comWhat is the TLC Diet?July 8 at 7:59 AM | news-medical.netNThis TLC star bares it all on stage while another rushes into a new relationshipJuly 8 at 7:59 AM | msn.com‘Virgins’ new episode on TLC tonight, how to watch for freeJuly 8 at 7:59 AM | masslive.comMFans Can't Believe TLC's Dr. Now 'Finally Smiled at Something' in 'Adorable' New VideoJuly 8 at 7:59 AM | msn.comAngelo Dawkins Feared Career-Ending Knee Injury In TLC Match – ‘I’m Afraid Of Heights!’July 6, 2025 | ewrestlingnews.comEThe True and Tragic Story of TLC’s Lisa ‘Left Eye’ LopesJuly 4, 2025 | yahoo.com‘90 Day Fiancé: Happily Ever After?’ Season 9 Cast Photos: Meet The 8 Couples Returning To TLC SeriesJuly 4, 2025 | msn.comTLC Recovery House celebrating 4th Anniversary and Recovery RallyJuly 4, 2025 | msn.comAdult virgins break taboos and take huge emotional risks in tonight’s must-see TLC episodeJuly 1, 2025 | msn.comTLC’s ‘Virgins’ airs new episode tonight - How to watch for freeJuly 1, 2025 | masslive.comM‘Match Me Abroad’ season 2, episode 2; how to watch TLC realityJune 29, 2025 | mlive.comMTLC ‘Virgins’ Star Rhasha Will Have You Blushing With Her Unique Definition of BDSM (Exclusive)June 27, 2025 | usmagazine.comUTLC brings colour, connection to Niche Market Art ShowcaseJune 26, 2025 | citizen.co.zaCPhiladelphia Leadership: Emily Gatto, Director, TLC WellnessJune 26, 2025 | msn.comManchester's TLC Foundation seeks $200,000 to avoid closing Diyeso-Lewis House for homeless childrenJune 26, 2025 | stamfordadvocate.comSHow to watch ‘Match Me Abroad’ Season 2 TLC dating show free or on demandJune 23, 2025 | msn.comTLC’s hit show ‘Match Me Abroad’ returns after 2-year break: How you can watch the new season freeJune 23, 2025 | msn.comStill A Virgin At 34, Reading Man Tries Tantra And Pickup Lines On New TLC ShowJune 12, 2025 | dailyvoice.comDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTHTX, GLYC, TLC, and NMTR Company DescriptionsGlycoMimetics NASDAQ:GLYC$0.16 -0.01 (-6.63%) Closing price 06/13/2025Extended Trading$0.16 0.00 (0.00%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.Theratechnologies NASDAQ:THTX$3.15 +0.01 (+0.32%) Closing price 04:00 PM EasternExtended Trading$3.15 0.00 (0.00%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Taiwan Liposome NASDAQ:TLCTaiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
